Skip to main
CVS
CVS logo

CVS Health (CVS) Stock Forecast & Price Target

CVS Health (CVS) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 33%
Buy 61%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

CVS Health reported a robust Health Services revenue of $49.27 billion, reflecting an 11.6% year-over-year growth that exceeded expectations, driven by a favorable pharmacy drug mix and brand inflation. The company's Retail pharmacy segment also demonstrated strong performance, with revenue of $36.21 billion, an 11.7% year-over-year increase fueled by rising prescription volumes, leading to positive trends in customer growth and retail market share in the front store. Furthermore, the acquisition of Oak Street Health is expected to enhance synergies across CVS's existing business lines, contributing to an optimistic outlook for long-term growth in both Healthcare Delivery and Pharmacy and Consumer Wellness segments.

Bears say

The analysis reveals a negative outlook for CVS Health based on key financial metrics indicating significant challenges ahead. Specifically, the company's EPS growth is projected to be approximately 5% below current estimates due to headwinds in Medicare Advantage utilization, alongside a 7% year-over-year decline in segment adjusted operating income and a decrease in claims processed by 1.8%. Additionally, CVS's valuation is anticipated to decline to 9.8x, reflecting the market's apprehension regarding membership losses, regulatory scrutiny, and increasing competition, which could all contribute to the erosion of its market share and financial stability.

CVS Health (CVS) has been analyzed by 18 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 61% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CVS Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CVS Health (CVS) Forecast

Analysts have given CVS Health (CVS) a Buy based on their latest research and market trends.

According to 18 analysts, CVS Health (CVS) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $87.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $87.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CVS Health (CVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.